Alligator Bioscience Future Growth
Future criteria checks 1/6
Alligator Bioscience is forecast to grow earnings and revenue by 58.6% and 9.2% per annum respectively. EPS is expected to grow by 37.8% per annum. Return on equity is forecast to be -166.2% in 3 years.
Key information
58.6%
Earnings growth rate
37.8%
EPS growth rate
| Biotechs earnings growth | 31.1% |
| Revenue growth rate | 9.2% |
| Future return on equity | -166.2% |
| Analyst coverage | Low |
| Last updated | 06 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 131 | -58 | -66 | -53 | 2 |
| 12/31/2025 | 136 | -72 | -196 | -75 | 2 |
| 12/31/2024 | 266 | -1 | -201 | 94 | 3 |
| 12/31/2023 | 59 | -249 | -192 | -189 | N/A |
| 9/30/2023 | 68 | -232 | -185 | -182 | N/A |
| 6/30/2023 | 53 | -231 | -177 | -175 | N/A |
| 3/31/2023 | 40 | -213 | -178 | -177 | N/A |
| 12/31/2022 | 36 | -193 | -173 | -173 | N/A |
| 9/30/2022 | 21 | -177 | -159 | -159 | N/A |
| 6/30/2022 | 20 | -163 | -149 | -148 | N/A |
| 3/31/2022 | 18 | -152 | -139 | -139 | N/A |
| 12/31/2021 | 13 | -142 | -127 | -127 | N/A |
| 9/30/2021 | 8 | -139 | -125 | -125 | N/A |
| 6/30/2021 | 5 | -133 | -128 | -128 | N/A |
| 3/31/2021 | 6 | -133 | -127 | -127 | N/A |
| 12/31/2020 | 6 | -143 | -141 | -141 | N/A |
| 9/30/2020 | 5 | -169 | -161 | -160 | N/A |
| 6/30/2020 | 9 | -194 | -187 | -185 | N/A |
| 3/31/2020 | 4 | -209 | -199 | -197 | N/A |
| 12/31/2019 | 4 | -210 | -183 | -181 | N/A |
| 9/30/2019 | 30 | -181 | -174 | -172 | N/A |
| 6/30/2019 | 26 | -164 | -156 | -154 | N/A |
| 3/31/2019 | 26 | -152 | -144 | -141 | N/A |
| 12/31/2018 | 27 | -150 | -112 | -104 | N/A |
| 9/30/2018 | 53 | -107 | -112 | -97 | N/A |
| 6/30/2018 | 54 | -93 | -97 | -80 | N/A |
| 3/31/2018 | 55 | -86 | -89 | -71 | N/A |
| 12/31/2017 | 57 | -64 | -114 | -100 | N/A |
| 9/30/2017 | 12 | -96 | N/A | -80 | N/A |
| 6/30/2017 | 15 | -77 | N/A | -76 | N/A |
| 3/31/2017 | 18 | -91 | N/A | -41 | N/A |
| 12/31/2016 | 59 | -48 | N/A | -38 | N/A |
| 9/30/2016 | 55 | -68 | N/A | -52 | N/A |
| 12/31/2015 | 292 | 207 | N/A | 205 | N/A |
| 12/31/2014 | 1 | -77 | N/A | -63 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7AL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7AL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7AL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 7AL's revenue (9.2% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 7AL's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7AL is forecast to be unprofitable in 3 years.